CRISPR: a new method for genetic engineering – A prokaryotic immune component may potentially open a new era of gene silencing

I Amelio¹ and G Melino*¹,²,³

Cell Death and Differentiation (2015) 22, 3–5; doi:10.1038/cdd.2014.39; published online 4 April 2014

Last year three different groups led by Feng Zhang¹ at the Broad Institute, George Church² at Harvard Medical School, Jin-Soo Kim³ at Seoul National University and Jennifer Doudna⁴ at the University of California Berkeley, have adapted the prokaryotic immunity component, Clustered, Regularly Interspaced, Short Palindromic Repeats (CRISPR), to achieve genome engineering in mammalian cells. The impact of this approach was immediate; within a few months, several scientific reports have implemented or adapted this technique, highlighting its potential power. How effective is this new technology and will it render obsolete classical RNA interference and conventional in vivo mouse knockout strategies? And importantly, will it have an impact on the lives of the non-scientific population, such as by accelerating the generation of genetically modified foodstuffs and opening the possibility to correct and cure human genetic diseases?

Effective genome-editing systems are the Holy Grail for molecular biologists although the methods currently in use appear cumbersome by comparison with the CRISPR technology. CRISPR has only been developed as a result of the continued interest of biologists in elementary organisms, and the identification in prokaryotes of an innovative tool with which to modify the mammalian genome.

CRISPR is a natural RNA-guided DNA nuclease system used by archaea and bacteria to protect against invasive phage or plasmid DNAs. The CRISPR system is genomically encoded by the prokaryotic chromosome and includes a variable number of short repeats separated by non-repetitive spacer sequences, which are derived from previously encountered foreign DNAs. These spacers can match ‘proto-spacer’ sequences of invasive DNAs, functioning as a genomically recorded immunological memory. This region is flanked by a ‘leader’ sequence and by cas genes. The cas genes encode the protein component of the interference machinery. In the active machinery, the Cas protein loaded with the mature CRISPR RNA (crRNA) is delivered to the target DNA by double-strand base pair complementarity, and the CRISPR-associated nucleases cleave the invader nucleic acid (Figure 1a). The Cas9 protein, a type II CRISPR-associated Cas, exerts an endonuclease function by causing double-strand breaks (DSBs) in DNA. Exploiting the Cas9’s activity and designing crRNA (also named guide RNAs, gRNA) to target mammalian genome sequences, Zhang, Church, Kim and Doudna have developed a method to surgically operate on any genomic region. Transfection of mammalian expression vectors containing CRISP components, including a nuclear-localized Cas9 protein, resulted in the disruption of intended target genes in different cell lines. Cas9-dependent DSBs were generated at the designed loci and consequent activation of the mutagenic non-homologous end joining (NHEJ) machinery finalized gene disruption with reasonable efficiency (Figure 1b).

What about specificity and off-targets effects? One of the major limitations of the widely used genome-editing technologies based on transcription activator-like effector nucleases (TALENs) and zinc finger nucleases (ZNFs) is their off-target effects.⁶,⁷ Homologous recombination minimizes off-target effects of CRISPR. A mutant form of Cas9 (a nickase endonuclease), generating only DNA single-strand breaks, yielded similar homologous recombination but a lower NHEJ rate, thus reducing the NHEJ-dependent insertions, deletions and chromosomal rearrangements. Most of the potential of CRISPR indeed lies in the flexibility of the Cas9 protein. On the other hand, the possibility to design gRNAs for every genomic locus boosts the potential of this technology. With a catalytically active Cas9 protein, the CRISPR approach can generate gene disruption, whereas a defective Cas9 (dCas9) can either enable or disable the expression of a defined gene. Coupling dCas9 with a transcriptional activator or repressor has made possible the manipulation of specific gene transcription without altering genomic sequences.⁶ A system, called CRISPRi, employs a dCas9 lacking endonuclease activity that, when coexpressed with a gRNA, generates a DNA recognition complex that can specifically interfere with transcriptional elongation, RNA polymerase binding or transcription factor binding (Figure 1c).⁹ However, the genomic-editing power of CRISPR goes beyond gene disruption. The cellular homologous recombination machinery can replace the DNA locus with an engineered donor DNA fragment, containing a region with homology to the DSB site.

¹Medical Research Council, Toxicology Unit, Hodgkin Building, Leicester University, Lancaster Road, PO Box 138, Leicester LE1 9HN, UK; ²Biochemistry Laboratory, IDI-IRCCS, Rome, Italy and ³Department of Experimental Medicine and Surgery, University of Rome ‘Tor Vergata’, 00133 Rome, Italy
*Corresponding author: G Melino, Department of Experimental Medicine, University of Rome, 00133 Rome, Italy. Tel: +39 06 204 27 299; Fax: +39 03 204 27290; E-mail: gm89@leicester.ac.uk
This method enables the opportunity to integrate external DNA sequences into the genome. In addition, by adapting CRISPR as an imaging tool it acquires the potential to significantly improve the capacity to study genomic loci in live human cells. Using an EGFP-tagged endonuclease-deficient Cas9 protein and an optimized sgRNA, the Huang group reported effective imaging of repetitive elements in telomeres and coding genes in living cells (Figure 1c). Now, the inventors of CRISPR-Cas9, Zhang group, have adapted their method in a genome-wide knockout screen of human cells. Using lenti-CRISPR, they have targeted 18,080 genes in melanoma and embryonic stem cells, and cell with a library of 64,751 unique gRNAs. However, as for all the possible applications, being a particular new technology the limitations of CRISPR usage in this approach are still under careful assessment.

Heritable gene targeting in the mouse and rat has also been achieved by the CRISPR system. The generation of a double-gene knockout rat was obtained with a single microinjection, and the germline-transmission efficiency was reasonably high in both mice and rats. In plants, CRISPR has been shown to effectively inactivate multiple genes in rice and wheat. This application in plants has the potential, for example, to confer resistance to parasitic organisms.

CRISPR allows the possibility to knockout genes in cells, to easily alter simultaneously multiple genes to study their interactions, and to create animal models much more quickly than before. The opportunity to precisely and selectively manipulate genomes is potentially opening a new era in genetic engineering. The cost- and time-efficiency of this technology compared with previous methods should boost its diffusion not only throughout basic science, but also in...
agriculture and medicine. Indeed, if high-fidelity target recogni-
tion is confirmed, the biggest challenge ahead for CRISPR is to
correct human disease-associated mutations, finally providing
an effective gene therapy strategy for human genetic diseases.

1. Cong L et al. Science 2013; 339: 819–823.
2. Mali P et al. Science 2013; 339: 823–826.
3. Cho SW et al. Nat Biotechnol 2013; 31: 230–232.
4. Jinek M et al. Elife 2013; 2: e00471.
5. Wiedenheft B, Sternberg SH, Doudna JA. Nature 2012; 482: 331–338.
6. Mussolino CM et al. Nucleic Acids Res 2011; 39: 9283–9293.
7. Kim E et al. Genome Res 2012; 22: 1327–1333.
8. Gilbert LA et al. Cell 2013; 154: 442–451.
9. Qi LS et al. Cell 2013; 152: 1173–1183.
10. Chen B et al. Cell 2013, 155: 1479–1491.
11. Wang T et al. Science 2014; 343: 80–84.
12. Shalem O et al. Science 2014; 343: 84–87.
13. Li D et al. Nat Biotechnol 2013; 31: 681–683.
14. Shan Q et al. Nat Biotechnol 2013; 31: 686–688.